Diagnosis, grading and management of toxicities from immunotherapies in children...
In this Consensus Statement, members of several international societies collaborated to provide updated comprehensive recommendations for the care of children, adolescents and young adults receiving cancer immunotherapies.
SITC clinical practice guideline on immune effector cell-related adverse events
The SITC convened a panel to discuss the recognition and management of common toxicities in the context of IEC treatment, including baseline laboratory parameters for monitoring, timing to onset, and pharmacological interventions, ultimately forming evidence- and consensus-based recommendations to assist medical professionals in decision-making and to improve outcomes for patients.
Recommendations for screening, monitoring, prevention, and prophylaxis of infect...
Chimeric antigen receptor (CAR) T-cell therapy is one of the most promising emerging treatments for B-cell malignancies. Recently, two CAR T-cell products (axicabtagene ciloleucel and tisagenlecleucel) have been approved for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia; many other CAR-T constructs are in research for both hematological and non-hematological diseases.